REVVITY, INC. RVTY
REVVITY, INC. (RVTY) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.26% (safety: safe). FY2025 revenue was $2.9B at a 8.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-05 | Evercore ISI Group | Outperform (main) |
| 2026-07-06 | Evercore ISI Group | Outperform (main) |
| 2026-05-07 | Barclays | Equal-Weight (main) |
| 2026-05-06 | JP Morgan | Neutral (main) |
| 2026-05-06 | TD Cowen | Buy (main) |
| 2026-05-06 | Stifel | Hold (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.075 |
| Retained earnings / assets | 0.498 |
| EBIT / assets | 0.029 |
| Equity / liabilities | 1.474 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RVTY | REVVITY, INC. | 6/9 | 3.86 | 52.3 | +3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | 5/9 | 6.54 | 10.7 | +0.7% |
| WAT | WATERS CORP /DE/ | 4/9 | 10 | 55.1 | +7% |
| BRKR | BRUKER CORP | 4/9 | 2.98 | — | +2.1% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | 5/9 | — | 29.4 | +4% |
| ILMN | ILLUMINA, INC. | 7/9 | 3.04 | 31.4 | -0.7% |
| TXG | 10x Genomics, Inc. | 4/9 | 1.63 | — | +5.2% |
About REVVITY, INC.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
FAQ
Is RVTY financially healthy?
REVVITY, INC.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does RVTY pay a dividend, and is it safe?
Yes. REVVITY, INC. pays a dividend yielding about 0.26% with a 13.6% payout ratio, rated “safe” for safety.
How profitable is RVTY?
In FY2025, REVVITY, INC. had a net margin of 8.4% and a return on equity of 3.3%.
Is RVTY overvalued or undervalued?
REVVITY, INC. trades at about 56.9× trailing earnings — above its 10-year norm (10-year range 19.3×–57.3×, median 30.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for RVTY?
The average Wall-Street price target for REVVITY, INC. is $121.07, about 2.7% above the recent price, from 15 analysts (consensus: buy).
Is RVTY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on REVVITY, INC.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 52.3×, a dividend yield of 0.26%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-28. Facts plus Stocktoria's own computed scores — not investment advice.